Janssen Develops TREMFYA® One-Press Patient-controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis

The Janssen Pharmaceutical Companies of Johnson & Johnson developed TREMFYA® One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis.

TREMFYA® is the first FDA-approved medication to offer the One-Press patient-controlled injector. TREMFYA is administered as a 100 mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4.

The patient-controlled injector, TREMFYA should be used under the guidance and supervision of a physician, and patients may self-inject with TREMFYA One-Press after physician approval and proper training. One-Press fits comfortably in the hand and offers a controlled injection that hides the needle throughout the process.

The design of One-Press allows patients to control the rate and pressure of their injection. One-Press also includes a safety system that protects the needle after use. After three injections, patients still reported favorable outcomes with the usability of the One-Press device.

With the approval of One-Press, patients now have the option to self-administer TREMFYA with a novel device that is simple and intuitive to use.

In the double-blind, placebo-controlled ORION study, the safety and efficacy of TREMFYA administered with One-Press in patients with moderate-to-severe plaque psoriasis was evaluated.

The majority of injection-site reaction symptoms with One-Press were mild and transient in nature. The results of the ORION study showed the administration of TREMFYA with One-Press was safe and effective, providing patients with a new, more convenient way to inject their treatment.